Cargando…

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

INTRODUCTION: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maher, Toby M., Schlecker, Christina, Luedtke, Doreen, Bossert, Sebastian, Zoz, Donald F., Schultz, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589333/ https://www.ncbi.nlm.nih.gov/pubmed/36299369 http://dx.doi.org/10.1183/23120541.00240-2022

Ejemplares similares

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2022)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2023)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis
por: Nikolova, Sevdalina, et al.
Publicado: (2010)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Correction to: Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis
por: Nikolova, Sevdalina, et al.
Publicado: (2022)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
por: Moschetti, Viktoria, et al.
Publicado: (2018)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

The DNA binding and 3′-end preferential activity of human tyrosyl-DNA phosphodiesterase
por: Dexheimer, Thomas S., et al.
Publicado: (2010)

Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations
por: Jones, Steve, et al.
Publicado: (2023)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
por: Moschetti, Viktoria, et al.
Publicado: (2016)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure
por: Baliga, Reshma S., et al.
Publicado: (2018)

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework
por: Langford, Bryony, et al.
Publicado: (2021)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Two Phosphodiesterases from Ustilago Maydis Share Structural and Biochemical Properties with Non-Fungal Phosphodiesterases
por: Agarwal, Charu, et al.
Publicado: (2010)

The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis
por: Usmani, Omar S., et al.
Publicado: (2018)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o76548qhrrgcopnrqdejrd3lfl